ResMed, Inc. (RMD) Misses Q3 EPS by 2c
- AbbVie (ABBV) to Acquire Pharmacyclics (PCYC) for $21 Billion
- Wall Street Takes Sides Ahead of Apple Watch Event (AAPL)
- Unusual 11 Mid-Day Movers 3/5: (PEIX) (EYES) (KYTH) Higher; (CAPN) (DRAM) (GEF) Lower
- Etsy (ETSY) Files $100 Million IPO
- ECB Boosts FY15, FY16 Real GDP Outlook; Sees Avg. Inflation at 1.8% in FY17 (FXE) (UUP)
ResMed, Inc. (NYSE: RMD) reported Q3 EPS of $0.33, $0.02 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $314.8 million versus the consensus estimate of $326.32 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dot Hill Systems Corp. (HILL) Tops Q4 EPS by 2c
- Kroger (KR) Tops Q4 EPS by 14c; Issues Confident FY15 EPS Outlook
- MOCON (MOCO) Reports Q4 EPS of $0.20
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!